secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001104659-26-003071
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma files IND for flu drug TXM; ratutrelvir beats Paxlovid on symptom resolution in interim study
--------------------------------------------------------------------------------

- IND filed with FDA for tivoxavir marboxil (TXM) for influenza; final step for BARDA stockpile consideration.
- Interim Phase 2 data: ratutrelvir showed faster symptom resolution vs Paxlovid (12 vs 14 days, p<0.014).
- No viral rebound in ratutrelvir arm vs one in Paxlovid; fewer adverse events (7.6% mild dyspepsia vs 30% in comparator).
- Ratutrelvir showed consistent safety and efficacy in Paxlovid-ineligible patients (13 patients).
- Full study enrollment expected in January 2026; 95% of 90 patients enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926003071/0001104659-26-003071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926003071/tm263039d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-003071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer